Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Phase 3 IMagyn050 Trial in Ovarian Cancer Does Not Meet Primary End Point of PFS

July 13th 2020

Results from the phase 3 IMagyn050 trial showed that the addition of atezolizumab to bevacizumab, paclitaxel, and carboplatin did not meet the primary end point of progression-free survival for first-line treatment of women with newly diagnosed, advanced ovarian cancer.

Dr. Salani on the Current State of Biomarker Testing in Cervical Cancer

July 8th 2020

Ritu Salani, MD, MBA, discusses the current state of biomarker testing in cervical cancer.

Yale Cancer Center Study Validates Combination Therapy for Aggressive Endometrial Cancer

July 8th 2020

Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.

Dr. Monk on the Utility of Tisotumab Vedotin in Recurrent Cervical Cancer

July 1st 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of tisotumab vedotin in recurrent cervical cancer.

Tisotumab Vedotin Shows Favorable Activity in Recurrent or Metastatic Cervical Cancer

June 30th 2020

The antibody-drug conjugate tisotumab vedotin induced clinically meaningful and durable responses in patients who have relapsed or progressed on or after previous treatment for recurrent or metastatic cervical cancer.

Brown Spotlights Key ASCO Highlights in Gynecologic Malignancies

June 26th 2020

The field of gynecologic oncology gained a number of important updates at the 2020 ASCO Virtual Scientific Program. As part of the ASCO Direct Highlights webcast, Jubilee Brown, MD, provided insight on key trials that were presented at the program.

New Diagnostic Algorithms Have Prognostic Implications in Endometrial Cancer

June 25th 2020

Endometrial cancer tumor types are traditionally categorized through a combination of histologic molecular subtyping and clinical staging; however, the incorporation of new diagnostic algorithms may have clinical implications for treatment.

Dr. O’Malley on the Utility of Mirvetuximab in Ovarian Cancer

June 24th 2020

David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.

Novel ADC STRO-002 Shows Early Promise in Heavily Pretreated Epithelial Ovarian Cancer

June 23rd 2020

R. Wendel Naumann, MD, discusses the early results reported with STRO-002, the hope for this agent in the ovarian cancer space, and the next steps for this research.

Pembrolizumab Continues to Show Modest Clinical Activity in Advanced Ovarian Cancer

June 23rd 2020

Pembrolizumab demonstrated modest clinical activity in patients with advanced recurrent ovarian cancer.

Dr. Slomovitz on Sequencing Strategies for Endometrial Cancer

June 16th 2020

Brian M. Slomovitz, MD, discusses sequencing strategies for endometrial cancer.

Dr. Matulonis on Final Data From KEYNOTE-100 in Recurrent Ovarian Cancer

June 10th 2020

Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.

Nivolumab/Ipilimumab Induction Therapy Boosts Responses and Prolongs PFS in Epithelial Ovarian Cancer

June 10th 2020

The combination of nivolumab plus ipilimumab was found to induce a superior response rate and longer progression-free survival compared with nivolumab alone in patients with persistent or recurrent epithelial ovarian cancer.

Dr. Zakashansky on Repeat Exposure to PARP Inhibitors in Patients With Ovarian Cancer

June 8th 2020

Konstantin Zakashansky, MD, gynecologic oncologist and associate professor of Obstetrics, Gynecology and Reproductive Science at Mount Sinai Health System, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

Dr. Liu on Phase 2 Study Results of Adavosertib in Recurrent Uterine Serous Carcinoma

May 30th 2020

Joyce F. Liu, MD, MPH, discusses findings from a phase 2 study with the Wee1 inhibitor adavosertib in patients with recurrent uterine serous carcinoma.

Avelumab Controls hCG Levels Lead to Remissions in Gestational Trophoblastic Tumors

May 29th 2020

Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.

Maintenance Niraparib Boosts PFS in Phase 3 Study of Chinese Patients With Ovarian Cancer

May 29th 2020

Maintenance niraparib improved progression-free survival in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy, meeting the primary end point of the phase 3 NORA study.

Level 1 Evidence Needed to Drive Optimal Sequencing Strategies in Endometrial Cancer

May 20th 2020

Brian M. Slomovitz, MD, explaines the need to determine optimal sequencing strategies in endometrial cancer.

Level 1 Evidence Needed to Drive Optimal Sequencing Strategies in Endometrial Cancer

May 20th 2020

Brian M. Slomovitz, MD, explaines the need to determine optimal sequencing strategies in endometrial cancer.

Dr. Westin on Novel Targets in Endometrial Cancer

May 12th 2020

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.